BCL2 and B-cell chronic lymphocytic leukemia: Only one BCL2 inhibitor, ABT199 (Venetoclax), has been approved by the Food and Drug Administration (FDA) to treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Acute Myeloid Leukemia6,11,20.